<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>345</serviceExecutionTime><Drug id="100010"><DrugName>lymphocyte expansion molecule stimulator gene therapy (cancer/viral infection), ImmunarT</DrugName><DrugSynonyms><Name><Value>lymphocyte expansion molecule stimulator gene therapy (cancer/viral infection), ImmunarT</Value></Name><Name><Value>LEM stimulator gene therapy (cancer/viral infection), ImmunarT</Value></Name></DrugSynonyms><CompanyOriginator id="1116520">ImmunarT Ltd</CompanyOriginator><CompaniesSecondary><Company id="1116520">ImmunarT Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1116520" type="Company"><TargetEntity id="5047645483" type="organizationId">Immunart Ltd</TargetEntity></SourceEntity><SourceEntity id="344" type="ciIndication"><TargetEntity id="10047461" type="MEDDRA"/><TargetEntity id="D014777" type="MeSH"/><TargetEntity id="-1748727144" type="omicsDisease"/><TargetEntity id="854" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="344">Viral infection</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="4778">Gene therapy</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-02T03:27:44.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1116520" linkType="Company"&gt;ImmunarT&lt;/ulink&gt; was investigating a gene therapy that was designed to improve immunity by boosting the production of lymphocyte expansion molecule (LEM) that increases the proliferation of cytotoxic T cells, for the potential treatment of cancer and viral infection. In April 2015, the company planned to initiate human trials in three years. In May 2015, preclinical data were published [&lt;ulink linkID="1715692" linkType="Reference"&gt;1715692&lt;/ulink&gt;], [&lt;ulink linkID="1715424" linkType="Reference"&gt;1715424&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2015, the company planned to initiate human trials in three years [&lt;ulink linkID="1715424" linkType="Reference"&gt;1715424&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2015, preclinical data were published. Data demonstrated that LEM promoted antigen-dependent CD8+ T-cell proliferation, effector function, and memory cell generation in response to infection with lymphocytic choriomeningitis virus. Also, experiments in mice and human cells shown that the protein promotes the proliferation of cytotoxic T cells that kills cancer cells and cells infected with viruses [&lt;ulink linkID="1715692" linkType="Reference"&gt;1715692&lt;/ulink&gt;], [&lt;ulink linkID="1715424" linkType="Reference"&gt;1715424&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1116520">ImmunarT Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="344">Viral infection</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1116520">ImmunarT Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1116520">ImmunarT Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2015-01-23T00:00:00.000Z</StatusDate><Source id="1715692" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1116520">ImmunarT Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="344">Viral infection</Indication><StatusDate>2015-01-23T00:00:00.000Z</StatusDate><Source id="1715692" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=1715692" linkType="reference" linkID="1715692"&gt;1715692&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1715424" linkType="reference" linkID="1715424"&gt;1715424&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="100043"><DrugName>DHX-11</DrugName><DrugSynonyms><Name><Value>DHX-11</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1004998">Shenyang Pharmaceutical University</CompanyOriginator><CompaniesSecondary><Company id="1004998">Shenyang Pharmaceutical University</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1004998" type="Company"><TargetEntity id="5035524415" type="organizationId">Shenyang Pharmaceutical University</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-05-30T05:50:41.000Z</LastModificationDate><ChangeDateLast>2018-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-28T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1004998" linkType="Company"&gt;Shenyang Pharmaceutical University&lt;/ulink&gt;   was investigating DHX-11, for the potential treatment of cancer. In November 2015, it was in preclinical studies; at that time, the university was seeking to outlicense this project [&lt;ulink linkID="1708648" linkType="Reference"&gt;1708648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2015,  the university intended to develop DHX-11 as a class 1.1 drug in China  [&lt;ulink linkID="1708648" linkType="Reference"&gt;1708648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In August 2012, preclinical data in rats were published  [&lt;ulink linkID="1716193" linkType="Reference"&gt;1716193&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By January 2012, the project was funded by Liaoning government [&lt;ulink linkID="1716191" linkType="Reference"&gt;1716191&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1004998">Shenyang Pharmaceutical University</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-05-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1004998">Shenyang Pharmaceutical University</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2012-01-31T00:00:00.000Z</StatusDate><Source id="1716191" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>3 references added [&lt;ulink url="utility.reference?i_reference_id=1716193" linkType="reference" linkID="1716193"&gt;1716193&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1708648" linkType="reference" linkID="1708648"&gt;1708648&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1716191" linkType="reference" linkID="1716191"&gt;1716191&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>